Suppr超能文献

经皮冠状动脉介入治疗术后血小板反应性与缺血性卒中风险:ADAPT-DES 研究。

Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.

机构信息

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Cardiovascular Research Foundation, New York, New York.

Cardiovascular Research Foundation, New York, New York.

出版信息

JACC Cardiovasc Interv. 2018 Jul 9;11(13):1277-1286. doi: 10.1016/j.jcin.2018.01.263. Epub 2018 Jun 13.

Abstract

OBJECTIVES

The authors sought to investigate the association between P2Y reaction units (PRU) and the risk of ischemic stroke (IS) after successful coronary drug-eluting stents (DES) implantation.

BACKGROUND

The association between platelet reactivity on clopidogrel and the risk for ischemic cerebrovascular events remains unclear.

METHODS

Incidence, predictors, and prognostic impact of IS were evaluated among patients enrolled in the multicenter, prospective ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents) study. By protocol, patients were maintained on aspirin for 2 years and clopidogrel for at least 1 year. Baseline platelet reactivity on clopidogrel and aspirin were assessed by means of VerifyNow point-of-care assay after successful DES implantation.

RESULTS

Among 8,582 patients enrolled, 68 (0.8%) had an IS during 2-year follow-up. Across the spectrum of PRU, rates of IS were progressively greater as patients transitioned from the lowest quintile of PRU (more P2Y receptor inhibition; 2-year rate of 0.51%) to the highest quintile of PRU (less P2Y receptor inhibition; 2-year rate of 1.34%; adjusted p = 0.04). PRU >208 was independently associated with higher risk of IS at 2 years (adjusted hazard ratio 1.81; 95% confidence interval 1.08 to 3.04; p = 0.03). The association between higher PRU and risk for IS was also consistent in patients with versus without high CHADS-VASc score (p = 0.30) and in those on or off oral anticoagulation at discharge (p = 0.99). Occurrence of IS was strongly associated with increased risk of all-cause mortality at 2 years (adjusted HR: 4.16; 95% CI: 1.95 to 8.87; p < 0.0001).

CONCLUSIONS

Higher PRU was associated with increased risk of IS after coronary DES implantation. Ensuring adequate platelet P2Y receptor inhibition may reduce the risk of IS in this patient population. (Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents [ADAPT-DES]; NCT00638794).

摘要

目的

作者旨在研究血小板反应单位(PRU)与成功接受冠状动脉药物洗脱支架(DES)植入后的缺血性卒中(IS)风险之间的关联。

背景

氯吡格雷诱导的血小板反应性与缺血性脑血管事件风险之间的关系尚不清楚。

方法

多中心前瞻性 ADAPT-DES(药物洗脱支架双重抗血小板治疗评估)研究中评估了患者的 IS 发生率、预测因素和预后影响。根据方案,患者在接受 DES 植入后至少 1 年接受阿司匹林治疗 2 年。通过即时护理检测(VerifyNow 点-of-care assay)评估成功植入 DES 后氯吡格雷和阿司匹林的基线血小板反应性。

结果

在纳入的 8582 例患者中,8.0%(68 例)在 2 年随访期间发生 IS。在 PRU 的整个范围内,随着患者从血小板反应单位最低五分位(更强的 P2Y 受体抑制;2 年发生率为 0.51%)转变为血小板反应单位最高五分位(较弱的 P2Y 受体抑制;2 年发生率为 1.34%),IS 发生率逐渐增加,调整后的 p 值=0.04)。PRU>208 与 2 年内 IS 风险增加独立相关(调整后的危险比 1.81;95%置信区间 1.08 至 3.04;p=0.03)。在高 CHADS-VASc 评分患者与低 CHADS-VASc 评分患者之间(p=0.30)和出院时接受或未接受口服抗凝治疗的患者之间(p=0.99),更高的 PRU 与 IS 风险之间的关联也一致。2 年内发生 IS 与全因死亡率增加密切相关(调整后的 HR:4.16;95%CI:1.95 至 8.87;p<0.0001)。

结论

冠状动脉 DES 植入后较高的 PRU 与 IS 风险增加相关。确保充分的血小板 P2Y 受体抑制可能会降低该患者人群发生 IS 的风险。(药物洗脱支架双重抗血小板治疗评估 [ADAPT-DES];NCT00638794)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验